Pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source
Developing a machine learning-powered platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics
Focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine
Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range of modalities and therapeutic areas
Developing a small molecule therapeutics platform for addressing strongly validated yet historically undruggable targets in oncology, rare diseases, neurodegeneration and autoimmunity
Computational biotechnology company creating a novel class of medicines to precisely target disease biology
Developing first-in-class gene therapies, Anellovector™ therapies, using a novel viral vector platform based on its groundbreaking work on the human commensal virome
Developing drugs that reprogram cellular microenvironments to send signals intended to have curative effects.